About Natera
Natera (NASDAQ:NTRA) specializes in advanced genetic testing and diagnostics, offering solutions that span across prenatal health, cancer detection, and organ transplant health. With a strong focus on innovation, Natera continuously works on developing new technologies and tests to improve patient outcomes and support healthcare providers. The company's projects range from non-invasive prenatal tests (NIPT) to comprehensive cancer screening and monitoring tools, aiming to make personalized and predictive healthcare accessible. Natera's objectives are centered on advancing the field of genetic testing through research, collaborations, and by setting new standards in accuracy and reliability for their offerings, thus empowering individuals with critical health insights.
Snapshot
Operations
Products and/or services of Natera
- Panorama is a non-invasive prenatal test that screens for Down syndrome and other genetic conditions.
- Prospera is a transplant assessment tool that monitors organ health.
- Signatera is a personalized, tumor-informed assay for cancer recurrence detection.
- Horizon is a carrier screening test that assesses risk for passing on genetic conditions.
- Spectrum is a preimplantation genetic testing for aneuploidies, helping IVF patients.
- Empower is a hereditary cancer screening test identifying risk for common genetic conditions.
Natera executive team
- Dr. Matthew Rabinowitz Ph.D.Co-Founder & Executive Chairman
- Mr. Steven Leonard ChapmanCEO & Director
- Mr. John FeskoPresident & Chief Business Officer
- Mr. Michael B. Brophy M.B.A.Chief Financial Officer
- Mr. Solomon Moshkevich M.B.A.President of Clinical Diagnostics
- Mr. Jonathan Sheena M.Eng.Co-Founder & Director
- Ms. Olesya A. Anisimova CPAChief Accounting Officer
- Mr. Rishi KackerChief Technology Officer
- Mr. Eric A. Evans Ph.D.Chief Scientific Officer
- Mr. Daniel Rabinowitz L.L.M.Secretary & Chief Legal Officer